VCM
KNSA icon

Versant Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Versant Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.9K Buy
186
+20
+12% +$1.47K ﹤0.01% 2138
2026
Q2 		$10.6K Hold
166
– – ﹤0.01% 2211
2026
Q1 		$7.99K Hold
166
– – ﹤0.01% 2227
2025
Q4 		$6.85K Hold
166
– – ﹤0.01% 2136
2025
Q3 		$6.45K Hold
166
– – ﹤0.01% 2108
2025
Q2 		$4.59K Buy
+166
New +$4.23K ﹤0.01% 2185

Other funds holding KNSA

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Versant Capital Management's KNSA Position: Q3 2026 in Review

Versant Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 12% in Q3 2026, buying an estimated $1.47K and bringing the position to 186 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Versant Capital Management first reported a position in KNSA in Q2 2025 and has held it in 6 quarters since. 8 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Versant Capital Management held 186 shares of Kiniksa Pharmaceuticals worth $13.9K as of Q3 2026.
  • Versant Capital Management bought 20 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $1.47K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2138 holding.
  • Versant Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • 8 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.